|
1
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar
|
|
2
|
Serrano MJ, Rovira PS, Martinez-Zubiaurre
I, et al: Dynamics of circulating tumor cells in early breast
cancer under neoadjuvant therapy. Exp Ther Med. 4:43–48.
2012.PubMed/NCBI
|
|
3
|
Yamaguchi M, Kwong YL, Kim WS, et al:
Phase II study of SMILE chemotherapy for newly diagnosed stage IV,
relapsed, or refractory extranodal natural killer (NK)/T-cell
lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin
Oncol. 29:4410–4416. 2011. View Article : Google Scholar
|
|
4
|
Early Breast Cancer Trialists’
Collaborative Group (EBCTG). Peto R, Davies C, Godwin J, et al:
Comparisons between different polychemotherapy regimens for early
breast cancer: meta-analyses of long-term outcome among 100,000
women in 123 randomised trials. Lancet. 379:432–444. 2012.
View Article : Google Scholar
|
|
5
|
Fang YX and Gao WQ: Roles of microRNAs
during prostatic tumorigenesis and tumor progression. Oncogene.
33:135–147. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nazarov PV, Reinsbach SE, Muller A, et al:
Interplay of microRNAs, transcription factors and target genes:
linking dynamic expression changes to function. Nucleic Acids Res.
41:2817–2831. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Kouwenhove M, Kedde M and Agami R:
MicroRNA regulation by RNA-binding proteins and its implications
for cancer. Nat Rev Cancer. 11:644–656. 2011.PubMed/NCBI
|
|
8
|
Marcucci G, Maharry KS, Metzeler KH, et
al: Clinical role of microRNAs in cytogenetically normal acute
myeloid leukemia: miR-155 upregulation independently identifies
high-risk patients. J Clin Oncol. 31:2086–2093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Voorhoeve PM: MicroRNAs: Oncogenes, tumor
suppressors or master regulators of cancer heterogeneity? Biochim
Biophys Acta. 1805:72–86. 2010.PubMed/NCBI
|
|
11
|
Xiang Y, Ma N, Wang D, et al: MiR-152 and
miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity
by targeting DNMT1 directly: a novel epigenetic therapy independent
of decitabine. Oncogene. 33:378–386. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Östling P, Leivonen SK, Aakula A, et al:
Systematic analysis of microRNAs targeting the androgen receptor in
prostate cancer cells. Cancer Res. 71:1956–1967. 2011.PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cimmino A, Calin GA, Fabbri M, et al:
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl
Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou M, Liu Z, Zhao Y, et al:
MicroRNA-125b confers the resistance of breast cancer cells to
paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist
killer 1 (Bak1) expression. J Biol Chem. 285:21496–21507. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang CM, Zhao J and Deng HY: MiR-155
promotes proliferation of human breast cancer MCF-7 cells through
targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci.
20:792013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lal A, Navarro F, Maher CA, et al: miR-24
Inhibits cell proliferation by targeting E2F2, MYC, and other
cell-cycle genes via binding to ‘seedless’ 3′UTR microRNA
recognition elements. Mol Cell. 35:610–625. 2009.PubMed/NCBI
|
|
18
|
Powell-Coffman JA and Coffman CR:
Apoptosis: Lack of oxygen aids cell survival. Nature. 465:554–555.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Higgs G and Slack F: The multiple roles of
microRNA-155 in oncogenesis. J Clin Bioinforma. 3:172013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu M, Lang N, Chen X, et al: miR-185
targets RhoA and Cdc42 expression and inhibits the proliferation
potential of human colorectal cells. Cancer Lett. 301:151–160.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maroun CR and Rowlands T: The Met receptor
tyrosine kinase: a key player in oncogenesis and drug resistance.
Pharmacol Ther. 142:316–338. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li C, Wu JJ, Hynes M, et al: c-Met is a
marker of pancreatic cancer stem cells and therapeutic target.
Gastroenterology. 141:2218–2227. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang W, Mendoza MC, Pei X, et al:
Down-regulation of CMTM8 induces epithelial-to-mesenchymal
transition-like changes via c-MET/extracellular signal-regulated
kinase (ERK) signaling. J Biol Chem. 287:11850–11858. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang MK, Zhou HY, Yam JW and Wong AS:
c-Met overexpression contributes to the acquired apoptotic
resistance of nonadherent ovarian cancer cells through a cross talk
mediated by phosphatidylinositol 3-kinase and extracellular
signal-regulated kinase 1/2. Neoplasia. 12:128–138. 2010.
|
